Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Yi Zhang1†, Qi Jin1,2†, Zhihui Zhao1, Qing Zhao1, Xue Yu1,3, Lu Yan1, Xin Li1, Anqi Duan1, Chenhong An1, Xiuping Ma1, Changming Xiong1, Qin Luo1* and Zhihong Liu1*

1 Center for Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2 Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China, 3 Department of Cardiology, Qingdao Municipal Hospital, Qingdao, China

Background: Emerging evidence has showed that serum carbohydrate antigen 125 (CA 125) levels are associated with the severity and prognosis of heart failure. However, its role in pulmonary hypertension remains unclear. This study aimed to investigate the clinical, echocardiographic, hemodynamic, and prognostic associations of CA 125 in pulmonary hypertension.

Methods and Results: We conducted a retrospective cohort study of all idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients receiving CA 125 measurement in Fuwai Hospital (January 1, 2014–December 31, 2018). The primary end-point was cumulative 1-year clinical worsening-free survival rate. Linear regression was performed to assess the association between CA 125 and clinical, echocardiographic, and hemodynamic parameters. Cox proportional hazards models were used to assess the association between CA 125 and clinical worsening events. Receiver operating characteristic (ROC) curve analysis was performed to determine the predictive performance of CA 125. A total of 231 patients were included. After adjustment, CA 125 > 35 U/ml was associated with over 2 folds increased risk of 1-year clinical worsening. Further, ROC analysis showed that CA 125 provided additional predictive value in addition to the established pulmonary hypertension biomarker NT-proBNP.

Conclusion: CA 125 was associated with functional status, echocardiography, hemodynamics and prognosis of pulmonary hypertension.

Keywords: pulmonary hypertension, carbohydrate antigen 125, biomarkers, prognosis, severity
INTRODUCTION

Carbohydrate antigen 125 (CA 125), also known as mucin 16, is a glycoprotein synthesized by serosal cells in response to mechanical stress (congestion) or inflammatory stimuli (1–3). High serum CA 125 levels have been identified in malignancies such as ovarian, lung and gastrointestinal cancer (4). Currently, CA 125 is a widely used biomarker for the screening (5), monitoring (6) and risk stratification (7) of ovarian cancer. In addition, emerging evidence has linked serum CA 125 levels to non-malignant conditions such as cardiovascular disease (e.g., heart failure, pericardial diseases, and coronary artery disease) (8). More specifically, serum CA 125 levels were found to be associated with functional class (9), echocardiography (10), and hemodynamics (11) in heart failure. Furthermore, some studies have demonstrated the diagnostic and prognostic value of CA 125 in heart failure (12, 13). The capability of CA 125 to serve as a therapeutic target for heart failure has also been investigated, and the results were promising (14, 15).

As the release of CA 125 is irrelevant to the etiology of cardiac aggression, it should be considered a final organ damage marker (8). Thus, it may also play a role in pulmonary hypertension (PH). Unfortunately, there is still limited knowledge on this topic. Rahimi-Rad et al. reported that patients with PH had higher serum CA 125 levels than those without PH in chronic obstructive pulmonary disease (16). A similar phenomenon was also observed in congenital heart disease (17). Whether serum CA 125 levels are correlated with the severity and prognosis of PH remains unclear. In the present study, we aimed to investigate the correlations between CA125 and the functional status, echocardiography, hemodynamics, and prognosis of PH in a retrospective cohort.

MATERIALS AND METHODS

Study Design and Participants

This observational retrospective cohort study was conducted at Fuwai Hospital, Chinese Academy of Medical Sciences (Beijing, China). We screened all patients with idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH) who underwent right heart catheterization (RHC) from January 1, 2014, to December 31, 2018. Patients with CA 125 data and multiple clinical visit/hospitalization records were enrolled as long as they had a minimum of 1 year of follow-up data for outcomes. In addition, echocardiography-suspected PH patients with normal invasive pulmonary arterial pressure and CA 125 data were also recruited as the control group. The establishment of IPAH and CTEPH was based on the 2009 (before January 2016) or 2015 European Society of Cardiology/European Respiratory Society (ERS) guidelines (18, 19). Normal pulmonary arterial pressure was defined as the mean pulmonary arterial pressure (mPAP) <25 mm Hg (18, 19). By design, patients were excluded if they had (1) any malignancy, (2) inflammatory diseases, or (3) active infection. The following clinical data were collected via an electronic medical record system by two independent reviewers: demographics, etiology of PH, 6-minute walk distance (6MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, smoking history, alcohol consumption, World Health Organization functional class (WHO-FC), PH-specific medication, history of balloon pulmonary angioplasty/pulmonary endarterectomy, comorbidities, parameters derived from echocardiography and RHC, serum CA 125 levels, and follow-up data. The study protocol was approved by the Ethics Committee of Fuwai Hospital. Written informed consent was obtained from each patient.

CA 125 Measurement

Fasting venous blood samples were collected for CA 125 measurement on the first day of admission. Serum levels of CA125 were measured using a chemiluminescent microparticle immunoassay (product name: Access OV Monitor; Cat. No. 386357; Beckman Coulter Inc., Brea, CA, USA). Please refer to the manufacturer's website for the detailed methodology of the Access OV Monitor (https://mms.mckesson.com/product/586335/Beckman-Coulter-386357). The upper limit of normal for CA 125 was 35 U/ml with the Access OV Monitor. Accordingly, the included patients were divided into either the CA 125 > 35 U/ml group or the CA 125 ≤ 35 U/ml group.

RHC and Echocardiographic Examination

The detailed protocol for RHC has been provided in our previous publications (20–23). Briefly, with local anesthesia under continuous electrocardiographic monitoring, a 6 French pigtail catheter or 7 French Swan-Ganz catheter (Edwards Lifesciences World Trade Co., Ltd, Irvine, CA, USA) was advanced into the pulmonary artery through the right femoral vein or right internal jugular vein by placement of a 6 or 7 French vascular sheath. Correct catheter positioning was verified by fluoroscopy. Transducers were positioned at the midaxillary line and zeroed at atmospheric pressure. Transthoracic echocardiography was performed by experienced ultrasonologists in the Department of Echocardiography under the current guidelines (24).

Outcome

We considered the cumulative 1-year clinical worsening-free survival rate as the primary endpoint. Clinical worsening was defined as the occurrence of any of the following events: deteriorated WHO-FC, escalation of PH-specific therapy and rehospitalization due to heart failure or progression of PH. Endpoint events were adjudicated by two senior clinicians. Any discordance was resolved by the supervisors (QL and ZHL).

Statistical Analysis

Continuous variables are presented as the mean ± standard deviation. Categorical variables are given as counts. Comparisons between two groups were performed using an independent-sample t-test, the Mann–Whitney U-test or the chi-square test, as appropriate. Correlations between CA 125 and other variables were examined using the Spearman correlation coefficient. To adjust for potential confounding factors, associations with P < 0.100 were further assessed using multivariate linear regression analysis (enter method).
The Kaplan–Meier method was used to assess differences in the rate of 1-year clinical worsening events between patients with values above or below 35 U/ml; curves were compared with the log-rank test. The association between serum CA 125 levels and clinical worsening events was evaluated by a Cox proportional hazards model. Univariate Cox analysis was first performed to screen all prognostic factors. Variables with clinical significance or \( P < 0.100 \) in univariate analysis were selected for multivariate Cox analysis (enter method). We tested the Cox proportional hazards assumption for each covariate using Schoenfeld residuals. The linearity assumption for CA 125 was evaluated by restricted cubic splines with four knots. Collinearity diagnostics were examined for the potential presence of collinearity between independent variables in multivariate linear regression analysis and multivariate Cox analysis. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive performance of CA 125. Internal validation was performed using 500 bootstrap resamples (25, 26).

Values of CA 125 and NT-proBNP were logarithmically transformed (ln) and then used in correlation analysis, linear regression and the Cox proportional hazards model. No single missing value was replaced. A two-sided \( P < 0.05 \) was considered indicative of statistical significance. Data analysis was performed using SPSS (version 23.0), R-studio (version 1.4.1106), R (version 4.0.5), and MedCalc (version 19.7.2).

**RESULTS**

**Patient Enrolment**

We identified 231 (45.9%) eligible records for IPAH/CTEPH patients from the 503 records assessed; of the patients, 164 were IPAH and 67 were CTEPH. Furthermore, 84 patients with normal invasive pulmonary arterial pressure and CA 125 data were included as controls. A flow chart displaying the enrolment process is shown in Figure 1.

**Baseline Characteristics**

The baseline characteristics of all included patients are presented in Table 1. Among 231 patients with PH, 191 were categorized into the CA 125 ≤ 35 U/ml group and 40 into the CA 125 > 35 U/ml group. At baseline, 111 (48.1%) of 231 patients presented with WHO-FC III/IV, and 40 (17.3%) patients did not receive PH-specific medication. During the follow-up period, 73 (31.6%) patients experienced clinical worsening events. More specifically, 20 patients had deteriorated WHO-FC, 16 patients escalated their PH-specific therapy, and 37 patients were rehospitalized due to heart failure or progression of pulmonary hypertension. Among patients who experienced clinical worsening, 23 were in the CA 125>35 U/ml group, and 50 were in the CA 125 ≤ 35 U/ml group.

**Patients With PH vs. Control Group**

Compared to those in the control group, patients with PH were younger (40.0 ± 15.3 vs. 50.4 ± 16.2 years, \( P < 0.001 \)), had worse WHO-FC, 6MWD, echocardiographic and haemodynamic parameters, and had higher serum levels of NT-proBNP and CA 125 [17.3 (11.3, 25.8) vs. 9.5 (6.1, 18.2) U/ml, \( P < 0.001 \)].

**PH Patients With CA 125 > 35 U/ml vs. Those With CA 125 ≤ 35 U/ml**

Compared to those with CA 125 ≤ 35 U/ml, patients with CA 125 > 35 U/ml had lower mixed venous oxygen saturation (\( \text{SvO}_2 \)), lower cardiac index (CI) values, a larger right ventricular end-diastolic diameter (RVED), higher prevalence rates of hyperlipidaemia and pericardial effusion, higher mean right atrial pressure (mRAP), and higher serum levels of NT-proBNP and CA 125 [55.9 (43.7, 83.0) vs. 14.5 (10.6, 21.1) U/ml, \( P < 0.001 \)]. In addition, patients with CA 125 > 35 U/ml tended to have a smaller left ventricular end-diastolic diameter (LVED) (36.2 ± 6.6 vs. 38.2 ± 6.2 mm, \( P = 0.064 \)).

**CA 125 Is Weakly Associated With Established Markers of PH Severity**

As shown in Table 2, ln(CA 125) was weakly correlated with 6MWD, WHO-FC, ln(NT-proBNP), echocardiographic parameters (LVED, RVED, and pericardial effusion), and haemodynamic parameters [\( \text{SvO}_2 \), mRAP, CI and pulmonary vascular resistance (PVR)]. In addition, ln(CA 125) tended to correlate with pulmonary arterial wedge pressure (PAWP) (\( r = 0.123, P = 0.062 \)). However, no correlations were observed between ln(CA 125) and left atrial dimension (\( r = -0.066, P = 0.318 \)), left ventricular ejection fraction (\( r = 0.034, P = 0.605 \)), systolic pulmonary arterial pressure (\( r = -0.037, P = 0.585 \)), or mPAP (\( r = 0.106, P = 0.109 \)). Similar results were observed in the CTEPH and IPAH subgroups (Supplementary Tables 1, 2).

In multivariate linear regression analysis (enter method), we further assessed correlations between CA 125 and functional status (6MWD, WHO-FC, and NT-proBNP) and echocardiographic (LVED, RVED and pericardial effusion) and haemodynamic (\( \text{SvO}_2 \), mRAP, CI, PVR, and PAWP) parameters by adjusting for age, sex, and body mass index. The results showed that ln(CA 125) was still positively correlated with WHO-FC, ln(NT-proBNP), RVED, pericardial effusion, mRAP, and PAWP and negatively correlated with 6MWD, WHO-FC, ln(NT-proBNP), echocardiographic (LVED, RVED, and pericardial effusion), and haemodynamic parameters.

**CA 125 Is Associated With Prognosis of PH**

Kaplan–Meier analysis showed that IPAH/CTEPH patients with CA 125 > 35 U/ml had a lower cumulative one-year clinical worsening-free survival rate than those with CA 125 ≤ 35 U/ml (42.5 vs. 73.8%, \( P < 0.0001 \); Figure 2).

In univariate Cox analysis, 6MWD, ln(NT-proBNP), \( \text{SvO}_2 \), mRAP, PAWP, and CA 125 > 35 U/ml had a \( P < 0.100 \) (Table 3). Considering their clinical importance, age, WHO-FC and pericardial effusion were also selected for multivariate Cox analysis (enter method). Events per variable are often used to estimate the sample size needed in multiple Cox analyses, and the lowest acceptable number of events per...
variable is usually considered to be 10 (27). Given that 73 patients reached the primary endpoint in the present study, it was relatively safe for us to include a maximum of 7 independent variables into multivariate Cox analysis. Model 1 was adjusted for \(S_\text{O}_2\), 6MWD, ln(NT-proBNP), mRAP, and PAWP. Model 2 was adjusted for the variables in model 1 plus age. Model 3 was adjusted for the variables in model 1 plus hyperlipidemia. Model 4 was adjusted for the variables in model 1 plus WHO-FC. Model 5 was adjusted for the variables in model 1 plus pericardial effusion. In all 5 Cox models, CA 125 was found to be an independent predictor of clinical worsening (Table 4). The C statistic was 0.648 [95% CI: 0.577–0.718] for model 1, 0.652 [95% CI: 0.582–0.722] for model 2, 0.649 [95% CI: 0.578–0.720] for model 3, 0.649 [95% CI: 0.579–0.720] for model 4 and 0.647 [95% CI: 0.576–0.718] for model 5. Using bootstrap validation, the optimism-corrected C statistic was 0.609 for model 1, 0.606 for model 2, 0.603 for model 3, 0.604 for model 4 and 0.602 for model 5, indicating that the predictive ability of the models is relatively stable in future patients. We did not observe statistically significant deviations from the proportional hazards assumption in any of the Cox models (Supplementary Table 3). When modeled as restricted cubic splines, CA 125 showed a linear association with the HR for clinical worsening (Supplementary Figure 1). No problems with collinearity were detected in multivariate Cox analysis (variance inflation factor < 5). Subgroup analysis also showed that CA 125 was an independent predictor of clinical worsening in CTEPH and IPAH (Supplementary Tables 4–7).

**CA 125 Provided Additional Predictive Value in Combination With NT-proBNP**

To provide better insight into the predictive value of CA 125 for clinical worsening, we benchmarked it against the established

---

**FIGURE 1** | Flow diagram of patient enrollment and exclusion. CA 125, Carbohydrate antigen 125; CTEPH, Chronic thromboembolic pulmonary hypertension; IPAH, Idiopathic pulmonary arterial hypertension.
PH biomarker NT-proBNP (18). The areas under the curve for CA 125, NT-proBNP, and combined CA 125 and NT-proBNP were 0.604 (95% CI 0.537–0.667), 0.573 (95% CI 0.507–0.638), and 0.637 (0.571–0.699), respectively. The area under the curve of CA 125 + NT-proBNP was significantly higher than that of NT-proBNP alone (P = 0.0233), as shown in Figure 3. No significant differences were observed between CA 125 and NT-proBNP (P = 0.5108) or CA 125 and CA 125 + NT-proBNP (P = 0.2710).

**TABLE 1 | Basic characteristics of control group and patients with PH.**

| Variables | Control (n=84) | CA 125 ≤ 35 U/ml (n=191) | CA 125 > 35 U/ml (n=40) | P-value* |
|-----------|---------------|--------------------------|--------------------------|---------|
| Age, years | 50.4 ± 16.2 | 40.0 ± 15.3² | 40.2 ± 15.2² | 38.9 ± 16.0² | 0.500 |
| Female gender, no. | 62 (73.8%) | 158 (68.4%) | 131 (68.6%) | 27 (67.5%) | 0.893 |
| BMI, kg/m² | 23.0 ± 3.9 | 23.2 ± 3.5 | 23.3 ± 3.5 | 22.8 ± 3.4 | 0.354 |
| IPAH+CTEPH, no. | – | 164/67 | 136/55 | 28/12 | 0.879 |
| 6 MMD, m | 454.4 ± 96.2 | 420.4 ± 100.4¹ | 424.0 ± 101.0 | 398.9 ± 96.2² | 0.259 |
| NT-proBNP, pg/ml | 135.0 (53.3, 314.9) | 880.0 (170.3, 1908.0)² | 712.9 (151.5, 1705.0)² | 1,375.0 (888.7, 3206.5)² | 0.002 |
| Smoking, no. | 12 (14.3%) | 29 (12.6%) | 21 (11.0%) | 8 (20.0%) | 0.118 |
| Alcohol intake, no. | 13 (15.5%) | 22 (9.5%) | 16 (8.4%) | 6 (15.0%) | 0.194 |
| WHO-FC | – | – | – | – | 0.007 |
| I or II, no. | 71 (84.5%) | 120 (51.9%) | 107 (56.0%) | 13 (32.5%) | 0.376 |
| II or IV, no. | 13 (15.5%) | 111 (48.1%) | 84 (44.0%) | 27 (67.5%) | 0.044 |
| PH specific medication | – | – | – | – | 0.220 |
| None, no. | – | – | – | – | 0.100 |
| Mono or combination therapy, no. | – | – | – | – | 0.017 |
| Systemic hypertension, no. | 25 (29.8%) | 45 (19.5%) | 40 (20.9%) | 5 (12.5%) | 0.785 |
| Diabetes mellitus, no. | 4 (4.8%) | 11 (4.8%) | 9 (4.7%) | 2 (5.0%) | 0.002 |
| Hyperlipidemia, no. | 15 (17.9%) | 22 (9.5%)³ | 22 (11.5%) | 0 (0%) | 0.001 |
| Echocardiography | – | – | – | – | <0.001 |
| LVEF, % | 63.4 ± 6.4 | 63.3 ± 5.8 | 63.3 ± 5.8 | 63.0 ± 5.7 | 0.722 |
| LA, mm | 34.3 ± 5.9 | 31.0 ± 5.5⁴ | 30.8 ± 5.0⁴ | 31.8 ± 7.5⁴ | 0.064 |
| LVED, mm | 44.5 ± 4.7 | 37.8 ± 6.3⁴ | 36.2 ± 6.2⁴ | 36.2 ± 6.6⁴ | <0.001 |
| RVED, mm | 25.6 ± 6.6 | 32.2 ± 6.6⁴ | 31.2 ± 6.4⁴ | 33.7 ± 6.5⁴ | 0.096 |
| mPAP, mm Hg | 47.0 ± 10.0 | 86.7 ± 26.0⁴ | 87.85 ± 27.2⁴ | 81.1 ± 18.9⁴ | <0.001 |
| Precordial effusion, no. | 7 (8.3%) | 32 (13.9%) | 18 (9.4%) | 14 (35.0%)³ | 0.001 |
| Hemodynamics | – | – | – | – | <0.001 |
| SvO₂, % | 76.0 ± 5.8 | 67.1 ± 6.5⁴ | 67.8 ± 6.2⁴ | 63.9 ± 7.4⁴ | 0.791 |
| mRAP, mm Hg | 3.0 (1.0, 5.0) | 5.0 (2.0, 8.0)² | 4.0 (2.0, 7.0)² | 7.0 (3.3, 13.8)² | 0.001 |
| mPAP, mm Hg | 15.2 ± 3.2 | 51.2 ± 13.4² | 51.3 ± 13.5² | 50.9 ± 13.3² | 0.918 |
| CI, L/min/m² | 3.7 ± 0.8 | 3.0 ± 1.0² | 3.1 ± 1.0² | 2.7 ± 0.9² | 0.018 |
| PVR, Wood units | 1.2 ± 0.8 | 10.7 ± 5.1² | 10.6 ± 5.2² | 11.3 ± 4.4² | 0.227 |
| PAWP, mm Hg | 8.3 ± 3.3 | 7.7 ± 3.4 | 7.6 ± 3.2 | 8.5 ± 4.2 | 0.138 |
| CA125, U/ml | 9.5 (6.1, 18.2) | 17.3 (11.3, 25.8)² | 14.5 (10.6, 21.1)² | 55.9 (43.7, 83.0)³ | 0.001 |

Data are presented as mean ± standard deviation, median (range) or number (percentage). BMI, Body mass index; BPA, balloon pulmonary angioplasty; CA 125, Carbohydrate antigen 125; CI, Cardiac index; CTEPH, Chronic thromboembolic pulmonary hypertension; IPAH, Idiopathic pulmonary arterial hypertension; LA, Left atrium dimension; LVED, Left ventricular end-diastolic diameter; LVEF, Left ventricular ejection fraction; mPAP, Mean pulmonary arterial pressure; mRAP, Mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAWP, Pulmonary arterial wedge pressure; PAH, Pulmonary arterial hypertension; PEA, Pulmonary endarterectomy; PH, Pulmonary hypertension; PVR, Pulmonary vascular resistance; RV ED, Right ventricular end-diastolic diameter; 6MWD, 6-min walk distance; sPAP, Systolic pulmonary arterial pressure; SvO₂, Mixed venous oxygen saturation; WHO-FC, World Health Organization functional class. ¹Only for patients with CTEPH. ²CA 125 > 35 U/ml compared with CA 125 ≤ 35 U/ml. ³P < 0.05, compared with control group. ⁴P <0.001, compared with control group. Bold values means their P value < 0.100.

**DISCUSSION**

In the present study, we found that serum CA 125 levels were weakly correlated with functional status (6MWD, WHO-FC, and NT-proBNP) and echocardiographic (LVED, RV ED, and pericardial effusion) and haemodynamic (SvO₂, mRAP, and CI) parameters of PH after adjustment. Moreover, CA 125 > 35 U/ml was found to be an independent predictor of 1-year clinical worsening in PH.
TABLE 2 | Correlations between carbohydrate antigen 125 and established markers of PH severity.

| Variables                  | Coefficient (r) | P-value | Adjusted coefficient (r)* | P-value |
|----------------------------|-----------------|---------|---------------------------|---------|
| 6MWD                       | −0.168          | 0.018   | −0.208                    | 0.004   |
| WHO-FC                     | 0.277           | <0.001  | 0.293                     | <0.001  |
| ln (NT-proBNP)             | 0.309           | <0.001  | 0.284                     | <0.001  |

Echocardiography

| Variables                  | Coefficient (r) | P-value | Adjusted coefficient (r)* | P-value |
|----------------------------|-----------------|---------|---------------------------|---------|
| LVEF                       | 0.034           | 0.605   |                           |         |
| LA                         | −0.066          | 0.318   |                           |         |
| LVED                       | 0.215           | 0.001   | −0.173                    | 0.017   |
| RVED                       | 0.306           | <0.001  | 0.382                     | <0.001  |
| sPAP                       | −0.037          | 0.585   |                           |         |
| Pericardial effusion       | 0.251           | <0.001  | 0.290                     | <0.001  |

Hemodynamics

| Variables                  | Coefficient (r) | P-value | Adjusted coefficient (r)* | P-value |
|----------------------------|-----------------|---------|---------------------------|---------|
| S\textsubscript{O}2         | −0.230          | <0.001  | −0.312                    | <0.001  |
| mRAP                       | 0.244           | 0.001   | 0.372                     | <0.001  |
| mPAP                       | 0.106           | 0.109   |                           |         |
| Cardiac index              | −0.243          | <0.001  | −0.208                    | 0.002   |
| PVR                        | 0.198           | 0.003   | 0.127                     | 0.068   |
| PAWP                       | 0.123           | 0.062   | 0.157                     | 0.018   |

In, Logarithmically transformed; LA, Left atrium dimension; LVED, Left ventricular end-diastolic diameter; LVEF, Left ventricular ejection fraction; mRAP, Mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAWP, Pulmonary arterial wedge pressure; PH, Pulmonary hypertension; PVR, Pulmonary vascular resistance; RVED, Right ventricular end-diastolic diameter; 6MWD, 6-min walk distance; S\textsubscript{O}2, Mixed venous oxygen saturation; WHO-FC, World Health Organization functional class.

*Each variable is adjusted for age, gender, body mass index by multivariate linear regression analysis. Bold values means their P-value < 0.100.

CA 125 Is Weakly Associated With Established Markers of PH Severity

Compared to patients with normal invasive pulmonary arterial pressure, patients with PH had higher serum CA 125 levels, which was consistent with the results seen in chronic obstructive pulmonary disease (16) and congenital heart disease (17).

WHO-FC, 6MWD, NT-proBNP, pericardial effusion, mRAP, CI, and S\textsubscript{O}2 are well-established prognostic markers of IPAH (18). We demonstrated that CA 125 was positively correlated with WHO-FC (9), NT-proBNP (28), RVED (10), pericardial effusion (10), mRAP (9, 11), and PAWP (9, 11) in PH, which was consistent with the results seen in heart failure. Additionally, we also found that CA 125 was negatively correlated with 6MWD, LVED, S\textsubscript{O}2, and CI in PH. Therefore, CA 125 may serve as a novel biomarker of severity in PH.

To date, it remains unclear what leads to CA125 overproduction in heart failure (29, 30). It has been hypothesized to correlate with so-called “stressed” mesothelial cells: (1) mesothelial cells are stimulated by tissue stretching/mechanical stress induced by fluid overload due to heart failure. (2) mesothelial cells are stimulated by inflammatory cytokine network activation (interleukin-1, tumor necrosis factor-α, lipopolysaccharides) (29, 31). PH is characterized by increased mPAP and high PVR, which cause right ventricular hypertrophy, and finally result in right-sided heart failure. Based on our results, we hereby offered a hypothesis to explain the relationship between CA 125 elevation and right heart failure. Elevated PVR increased the afterload of right ventricle, which would further cause right ventricular dilation and elevation of right atrial filling pressure, leading to elevated hydrostatic pressure and congestion, which would further cause both serosal mechanical stretch and third space fluid retention with resultant inflammation and cytokines release (8), ultimately resulting in the elevation of CA 125 (29).

CA 125 Is Associated With Prognosis of PH

Compared to those with CA 125 ≤ 35 U/ml, patients with CA 125 > 35 U/ml had higher serum levels of NT-proBNP and worse echocardiographic and haemodynamic parameters at baseline. In all 5 Cox models we constructed, CA125 > 35 U/ml was associated with an over 2-fold increased risk of 1-year clinical worsening, which was similar to the results seen in heart failure (32, 33). Furthermore, ROC analysis showed that CA 125 provided additional predictive value in addition to the established PH biomarker NT-proBNP (18). Due to its close relationship with congestion (8), CA 125 should be considered a final organ damage marker in cardiovascular diseases. This may explain why we found that CA 125 was a severe and prognostic marker in PH.

Clinical Implications

Based on the current knowledge, CA 125 has several merits for use as a biomarker in clinical practice: (1) it is inexpensive, widely available, and measurable with standard methods and has a relatively long half-life (5–7 days) (34–36). (2) It correlates with the severity and prognosis of PH, providing additional information in combination with established risk factors. Therefore, CA 125 may become a valuable tool in the management of PH in the near future. Further studies are needed to evaluate its capacity to monitor response to treatment, serving as a therapeutic target and predicting hard outcomes (such as mortality).

Limitations

As a retrospective cohort study, follow-up bias is our biggest concern. Two hundred nine patients with CA 125 data were excluded for not having a minimum of 1 year of follow-up data for outcomes (Figure 1). Among these 209 patients, 29 had CA 125 > 35 U/ml, and 180 had CA 125 ≤ 35 U/ml. In other words, these two groups had similar rates of loss to follow-up [29/(40 + 29), 42.0% for CA 125 > 35 U/ml; 180/(191 + 180), 48.5% for CA 125 ≤ 35 U/ml]. Moreover, the percentage of patients who reached the endpoint was higher in the CA 125 > 35 U/ml group (57.5 vs. 26.2%). Taken together, these results indicate that the effect size (e.g., hazard ratio) in the present study would be underestimated rather than exaggerated. Follow-up bias should not undermine our conclusion. The present study included only patients with IPAH/CTEPH, which may limit its generalizability to other etiologies of PH. We planned to conduct a comprehensive retrospective study to investigate the correlations between CA 125 and functional status and echocardiographic and hemodynamic parameters in all five groups of PH patients.
**TABLE 3** | Univariate cox analysis of proportional risks for 1-year clinical worsening.

| Variable                        | β      | Standard error | HR (95% CI)     | Wald   | P-value |
|---------------------------------|--------|----------------|-----------------|--------|---------|
| Age                             | 0.009  | 0.007          | 1.009 (0.994–1.024) | 1.470  | 0.225   |
| Female gender                   | −0.094 | 0.249          | 0.910 (0.559–1.484) | 0.811  | 0.707   |
| 6MWD                            | −0.002 | 0.001          | 0.998 (0.995–1.000) | 3.840  | 0.050   |
| ln (NT-proBNP)                  | 0.146  | 0.085          | 1.157 (0.979–1.368) | 2.918  | 0.088   |
| WHO-FC                          | 0.177  | 0.234          | 1.193 (0.754–1.889) | 0.568  | 0.451   |
| Smoking                         | 0.289  | 0.327          | 1.335 (0.703–2.355) | 0.778  | 0.378   |
| Alcohol intake                  | 0.048  | 0.398          | 1.105 (0.482–2.988) | 0.015  | 0.903   |
| Systemic hypertension           | −0.123 | 0.306          | 0.884 (0.485–1.611) | 0.162  | 0.687   |
| Diabetes mellitus               | −0.662 | 0.717          | 0.516 (0.127–2.104) | 0.852  | 0.356   |
| Hyperlipidemia                  | −0.380 | 0.463          | 0.684 (0.276–1.695) | 0.674  | 0.412   |
| LVEF                            | 0.000  | 0.020          | 0.982 (0.961–1.041) | 0.001  | 0.982   |
| LA                              | 0.004  | 0.021          | 1.004 (0.963–1.047) | 0.034  | 0.854   |
| LVED                            | −0.016 | 0.019          | 0.985 (0.949–1.021) | 0.695  | 0.404   |
| RVED                           | 0.016  | 0.017          | 1.017 (0.983–1.051) | 0.949  | 0.330   |
| sPAP                            | 0.005  | 0.004          | 1.005 (0.998–1.013) | 1.829  | 0.176   |
| Pericardial effusion            | 0.410  | 0.306          | 1.507 (0.827–2.746) | 1.797  | 0.180   |
| SvO2                            | −0.061 | 0.018          | 0.941 (0.909–0.974) | 12.023 | <0.001  |
| mPAP                            | 0.090  | 0.023          | 1.095 (1.047–1.145) | 15.558 | <0.001  |
| mPAP                            | 0.004  | 0.008          | 1.004 (0.988–1.020) | 0.218  | 0.641   |
| CI                              | −0.145 | 0.135          | 0.865 (0.664–1.127) | 1.156  | 0.282   |
| PVR                             | 0.016  | 0.022          | 1.016 (0.974–1.061) | 0.568  | 0.451   |
| PAWP                            | 0.064  | 0.035          | 1.067 (0.996–1.142) | 3.411  | 0.065   |
| CA 125 (category)²             | 0.975  | 0.253          | 2.650 (1.615–4.349) | 14.866 | <0.001  |

**CA 125**, Carbohydrate antigen 125; CI, Cardiac index; HR, Hazard ratio; LA, Left atrium dimension; LVED, Left ventricular end-diastolic diameter; LVEF, Left ventricular ejection fraction; ln, Logarithmically transformed; mPAP, Mean pulmonary arterial pressure; mRAP, Mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAWP, Pulmonary arterial wedge pressure; PVR, Pulmonary vascular resistance; RVED, Right ventricular end-diastolic diameter; 6MWD, 6-min walk distance; sPAP, Systolic pulmonary arterial pressure; SvO2, Mixed venous oxygen saturation; WHO-FC, World Health Organization functional class. ²CA 125 is classified into two groups, namely CA 125 ≤35 U/ml and CA 125 >35 U/ml. Bold values means their P-value < 0.100.
Table 4: Multivariate cox analysis of proportional risks for 1-year clinical worsening.

| Model | Variable       | β    | HR (95% CI)          | P-value |
|-------|----------------|------|----------------------|---------|
| 1     | CA 125 (category) | 0.860 | 2.362 (1.286–4.340) | 0.006   |
|       | S\textsubscript{O\textsubscript{2}} | −0.052 | 0.949 (0.904–0.996) | 0.035   |
|       | 6MWD            | −0.001 | 0.999 (0.996–1.002) | 0.576   |
|       | In (NT-proBNP)  | −0.042 | 0.959 (0.800–1.150) | 0.650   |
|       | mRAP            | 0.009  | 1.009 (0.942–1.080) | 0.802   |
|       | PAWP            | 0.040  | 1.041 (0.967–1.120) | 0.282   |
| 2     | CA 125 (category) | 0.876 | 2.401 (1.303–4.422) | 0.005   |
|       | S\textsubscript{O\textsubscript{2}} | −0.049 | 0.952 (0.906–1.000) | 0.050   |
|       | 6MWD            | −0.001 | 0.999 (0.997–1.002) | 0.691   |
|       | In (NT-proBNP)  | −0.037 | 0.964 (0.802–1.158) | 0.692   |
|       | mRAP            | 0.011  | 1.011 (0.944–1.083) | 0.759   |
|       | PAWP            | 0.037  | 1.037 (0.965–1.115) | 0.323   |
|       | Age             | 0.007  | 1.007 (0.990–1.024) | 0.424   |
| 3     | CA 125 (category) | 1.474 | 4.366 (1.306–14.590) | 0.017   |
|       | S\textsubscript{O\textsubscript{2}} | −0.028 | 0.972 (0.883–1.071) | 0.570   |
|       | 6MWD            | −0.003 | 0.999 (0.991–1.002) | 0.225   |
|       | In (NT-proBNP)  | −0.153 | 0.858 (0.603–1.211) | 0.396   |
|       | mRAP            | −0.013 | 0.987 (0.878–1.110) | 0.826   |
|       | PAWP            | 0.009  | 1.003 (0.883–1.139) | 0.969   |
|       | Hyperlipidemia  | −0.856 | 0.425 (0.088–2.043) | 0.285   |
| 4     | CA 125 (category) | 0.914 | 2.494 (1.339–4.645) | 0.004   |
|       | S\textsubscript{O\textsubscript{2}} | −0.054 | 0.948 (0.902–0.995) | 0.031   |
|       | 6MWD            | −0.001 | 0.999 (0.996–1.002) | 0.526   |
|       | In (NT-proBNP)  | −0.020 | 0.980 (0.810–1.186) | 0.835   |
|       | mRAP            | 0.012  | 1.012 (0.944–1.084) | 0.741   |
|       | PAWP            | 0.037  | 1.038 (0.963–1.118) | 0.331   |
|       | WHO-FC          | −0.244 | 0.784 (0.441–1.393) | 0.406   |
| 5     | CA 125 (category) | 0.843 | 2.323 (1.245–4.333) | 0.008   |
|       | S\textsubscript{O\textsubscript{2}} | −0.053 | 0.949 (0.904–0.996) | 0.034   |
|       | 6MWD            | −0.001 | 0.999 (0.996–1.002) | 0.807   |
|       | In (NT-proBNP)  | −0.048 | 0.953 (0.789–1.151) | 0.616   |
|       | mRAP            | 0.010  | 1.010 (0.943–1.081) | 0.783   |
|       | PAWP            | 0.040  | 1.040 (0.967–1.120) | 0.289   |
|       | Pericardial effusion | 0.095 | 1.100 (0.516–2.342) | 0.806   |

CA 125, Carbohydrate antigen 125; HR, Hazard ratio; ln, logarithmically transformed; mRAP, Mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAWP, Pulmonary arterial wedge pressure; 6MWD, 6-min walk distance; S\textsubscript{O\textsubscript{2}}, Mixed venous oxygen saturation; WHO-FC, World Health Organization functional class. *CA 125 is classified into two groups, namely CA 125 ≤35 U/ml and CA 125 >35 U/ml. Bold values means their P value < 0.100.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Ethics Statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Fuwai Hospital. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

ZL and QL contributed to the conception of the study. YZ and QJ performed the data analyses and wrote the manuscript. ZZ, QZ, and CX contributed significantly to analysis and manuscript preparation. XY, LY, XL, AD, CA, and XM contributed to data collection. All authors critically reviewed the manuscript for intellectual content and had final responsibility for the decision to submit for publication.

Funding

This research article was supported by National Natural Science Foundation of China (81370326 and 81641005); Beijing...
REFERENCES

1. O’Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers. (1998) 13:188–95. doi: 10.1177/172460089801300403
2. Barbieri RL, Nilofo JM, Bast RC Jr, Scatell E, Kisner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril. (1986) 45:630–4. doi: 10.1016/S0005-0282(16)49333-7
3. Halíá H, Steman UH, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer. (1986) 57:1327–9. doi: 10.1002/1097-0142(19860401)57:7<1327::AID-CNR28280570713>3.0.CO;2-Z
4. Lee G, Ge B, Huang TK, Zheng G, Duan J, Wang JH. Positive identification of CA125 pan cancer biomarker from serum samples of cancer patients. Cancer Biomark. (2010) 6:111–7. doi: 10.3323/CMB-2009-0134
5. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. (2009) 361:170–7. doi: 10.1056/NEJMcp0901926
6. Bouanène H, Miled A. [Tumor marker CA125: biochemical and molecular properties]. Bull Cancer. (2009) 96:597–601. doi: 10.1684/bdc.2009.0859
7. Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Groset EA, Gatanaga T, et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer. (2004) 101:106–15. doi: 10.1002/cncr.20314
8. Falcão F, de Oliveira FRA, da Silva M, Sobral Filho DC. Carbohydrate antigen CA-125 as a marker of ovarian cancer: clinical significance. Anticancer Res. (2012) 32:3139–44. doi: 10.21875/ancer.32.6.3139
9. Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Groset EA, Gatanaga T, et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer. (2004) 101:106–15. doi: 10.1002/cncr.20314
10. Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both chronic heart failure: relation to clinical severity, hemodynamics and doppler echocardiographic abnormalities, short-term prognosis. J Am Coll Cardiol. (2003) 41:1805–11. doi: 10.1016/S0735-1097(03)00311-5
11. Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both chronic heart failure: relation to clinical severity, hemodynamics and doppler echocardiographic abnormalities, short-term prognosis. J Am Coll Cardiol. (2003) 41:1805–11. doi: 10.1016/S0735-1097(03)00311-5
12. Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Groset EA, Gatanaga T, et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer. (2004) 101:106–15. doi: 10.1002/cncr.20314
13. Pektaş A, Ozguntürk R, Kula S, Çilsal E, Ogur AD, Tunaoglu FS. Biomarker and shear stress in secondary pediatric pulmonary hypertension. Turk J Med Sci. (2017) 47:1854–60. doi: 10.3906/sag-1609-13
14. Galí N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS) endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Respir J. (2015) 46:903–75. doi: 10.1083/eurheartj/ehv317
15. Galí N, Hooper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT). Eur Heart J. (2009) 30:2493–537. doi: 10.1093/eurheartj/ehp297
16. Rahimi-Rad MH, Rahimi P, Rahimi R, Gholamaghmad M. Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension. Pneumologia. (2014) 63:164–6.
17. Falcão F, de Oliveira FRA, da Silva M, Sobral Filho DC. Carbohydrate antigen CA-125 as a marker of ovarian cancer: clinical significance. Anticancer Res. (2012) 32:3139–44. doi: 10.21875/ancer.32.6.3139
18. burger RA, Darcy KM, DiSaia PJ, Monk BJ, Groset EA, Gatanaga T, et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer. (2004) 101:106–15. doi: 10.1002/cncr.20314
19. Falcão F, de Oliveira FRA, da Silva M, Sobral Filho DC. Carbohydrate antigen CA-125 as a marker of ovarian cancer: clinical significance. Anticancer Res. (2012) 32:3139–44. doi: 10.21875/ancer.32.6.3139
20. Tang Y, Luo Q, Liu Z, Ma X, Zhao Z, Huang Z, et al. Oxygen uptake efficiency slope predicts poor outcome in patients with idiopathic pulmonary arterial hypertension. J Am Heart Assoc. (2017) 6:e00537. doi: 10.1161/JAHA.116.00537
21. Zhang HL, Liu ZH, Wang Y, Xiong CM, Ni XH, He JG, et al. Acute responses to inhalation of iloprost in patients with pulmonary hypertension. Chin Med J. (2012) 125:2826–31. doi: 10.3760/cma.j.issn.0366-6999.2012.16.005
22. Yu X, Luo Q, Liu Z, Zhao Z, Zhao Q, An C, et al. Prevalence of iron deficiency in different subtypes of pulmonary hypertension. Heart Lung. (2018) 47:308–13. doi: 10.1016/j.thlung.2018.05.002
23. Jin Q, Luo Q, Yang T, Zheng Q, Yu X, Yan L, et al. Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. Respir Res. (2019) 20:250. doi: 10.1186/s12931-019-1211-y
24. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography. J Am Soc Echocardiogr. (2010) 23:685–713; quiz 786–688. doi: 10.1016/j.echo.2010.05.010
25. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. (1982) 247:2543–6. doi: 10.1001/jama.1982.0332043007030
26. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. (1996) 15:361–87. doi: 10.1002/(SICI)1097-0258(19960222)15:4<361::AID-SIM468>3.0.CO;2-4
27. Pavliou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. (2015) 351:h3868. doi: 10.1136/bmj.h3868

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.699904/full#supplementary-material

ACKNOWLEDGMENTS

We are especially thankful to Dr. Yang Wang and Yanyan Zhao (Department of Statistics, National Center for Cardiovascular Diseases, Beijing, China) for their invaluable and dedicated assistance with the statistics.
28. Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. *Eur J Heart Fail.* (2008) 10:556–9. doi: 10.1016/j.ejheart.2008.04.012

29. Hung CL, Hung TC, Lai YH, Lu CS, Wu YJ, Yeh HI. Beyond malignancy: the role of carbohydrate antigen 125 in heart failure. *Biomark Res.* (2013) 1:25. doi: 10.1186/2050-7771-1-25

30. Núñez J, Miñana G, Núñez E, Chorro FJ, Bodi V, Sanchis J. Clinical utility of antigen carbohydrate 125 in heart failure. *Heart Fail Rev.* (2014) 19:575–584. doi: 10.1007/s10741-013-9402-y

31. Frigy A, Belényi B, Kirchmaier Á, Fekete N, Szabó IA. Elevated CA-125 as humoral biomarker of congestive heart failure: illustrative cases and a short review of literature. *Case Rep Cardiol.* (2020) 2020:1642914. doi: 10.1155/2020/1642914

32. Shi C, van der Wal HH, Silljé HHW, Dokter MM, van den Berg F, Huizinga L, et al. Tumour biomarkers: association with heart failure outcomes. *J Intern Med.* (2020) 288:207–18. doi: 10.1111/jiom.13053

33. Chen YX, Wang XQ, Fang CF, Wang JF, Tang LJ. Value of BNP and tumour marker CA125 in patients with heart failure. *Acta Cardiol.* (2008) 63:501–6. doi: 10.2143/AC.63.4.2033050

34. Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, et al. Prognostic value of repeated serum CA125 measurements in first trimester pregnancy. *Eur J Obstet Gynecol Reprod Biol.* (2001) 97:168–73. doi: 10.1016/S0301-2115(00)00533-9

35. Colaković S, Lukić V, Mitrović L, Jelić S, Susnjar S, Marinčović J. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. *Int J Biol Markers.* (2000) 15:147–52. doi: 10.1177/17246008001500204

36. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. *Clin Chem.* (1999) 45:1695–707. doi: 10.1093/clinchem/45.10.1695

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Zhang, Jin, Zhao, Zhao, Yu, Yan, Li, Duan, An, Ma, Xiong, Luo and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*